Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone in Moderate to Severe Stuttering
NCT07734103Phase 2Recruiting
- Sponsor
- CSTrials
- Start
- Apr 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in stuttering comparing Lumateperone 21mg up to 42mg with Matching Placebo (2 arms). Primary endpoints: Comprehensive Brief Stuttering Assessment-SR at 7 days and Clinical Global Impression - Severity at 7 days. Started Apr 2026; status: recruiting.
02
Drugs
lumateperone
03
Conditions
stuttering
Beyond the preview
Go deeper on NCT07734103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07734103.